LUNAC THERAPEUTICS LIMITED - Profile & Financials

Accounts Submitted 28 Feb 2025

Confirmation Statement Submitted 24 Apr 2025

Net assets £-3.93M £317.82K 2024 year on year

Total assets £843.80K £353.81K 2024 year on year

Total Liabilities £4.77M £35.99K 2024 year on year

Charges 1

1 outstanding

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

Nexus Discovery Way Leeds Yorks LS2 3AA England

Credit Report

Discover LUNAC THERAPEUTICS LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2024

Type Total Exemption Full

Next accounts 31 December 2025

Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2019–2024)

Cash in Bank

£774.99k

Increased by £319.82k (+70%)

Net Assets

-£3.93M

Decreased by £317.82k (-9%)

Total Liabilities

£4.77M

Decreased by £35.99k (-1%)

Turnover

N/A

Employees

Debt Ratio

566%

Increased by 165 (+41%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2024 Dec Year End	2023 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share allotments and capital structure

3 Allotments 275,000 Shares £5.50m Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
23 Mar 2021	SERIES A PREFERRED	25,000	£500k	£20
6 May 2020	SERIES A PREFERRED	117,500	£2.35m	£20
20 Sept 2019	SERIES A PREFERRED	132,500	£2.65m	£20

Officers

4 active 3 resigned

Show resigned officers

						Status
Helen Philippou	Director	British	England	57	18 Apr 2018	Active
Mary Eugenie Canning	Director	Irish	United Kingdom	51	20 Sept 2019	Active
Mervyn Turner	Director	American	United States	79	4 Oct 2019	Active
Peter Michael Finan	Director	British	England	58	20 Sept 2019	Active

Shareholders

Shareholders (14)


University Of Leeds	15.3%	64,990	Ordinary	19 May 2021
The Wellcome Trust Limited	12.3%	52,269	Ordinary	19 May 2021
University Of Leeds	3.5%	15,000	Series A Preferred	19 May 2021

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Epidarex Capital Iii Uk,lp

United Kingdom

Active

Notified 20 Sept 2019

Nature of Control

Ownership Of Shares 25 To 50 Percent
Voting Rights 25 To 50 Percent

Caribou Property Ltd

Ceased 6 May 2020

Ceased

See All Controllers

Group Structure

EPIDAREX CAPITAL III UK, LP united kingdom part right to share surplus assets 25 to 50 percent

BRITISH BUSINESS FINANCE LTD united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors

EPIDAREX CAPITAL III UK GP, LP united kingdom

EPIDAREX MANAGEMENT LTD united kingdom

BRITISH BUSINESS BANK PLC united kingdom

LUNAC THERAPEUTICS LIMITED Current Company

Charges

1 outstanding

Documents

Company Filings

Date	Category	Description	Document
8 Sept 2025	Officers	Termination of Julian David Howell as director on 2025-06-30	View(1 page)
24 Apr 2025	Confirmation Statement	Confirmation statement made on 2025-04-17 with no updates	View(3 pages)
28 Feb 2025	Accounts	Annual accounts made up to 2024-05-31	View(11 pages)
18 Apr 2024	Confirmation Statement	Confirmation statement made on 2024-04-17 with no updates	View(3 pages)
12 Mar 2024	Persons With Significant Control	Cessation of Caribou Property Ltd as a person with significant control on 2020-05-06	View(1 page)